Artem Andrianov, PhD
Frankfurt/Rhein-Main
4830 Follower:innen
500+ Kontakte
Info
Turning lemons into lemonade is my specialty!
Master of turning challenges into…
Artikel von Artem Andrianov, PhD
Beiträge
Aktivitäten
-
Happy holidays to those that celebrate this time of year. Happy quiet time for those that reflect as well. is there any interest in a book club? or…
Happy holidays to those that celebrate this time of year. Happy quiet time for those that reflect as well. is there any interest in a book club? or…
Beliebt bei Artem Andrianov, PhD
-
For those of you who are not yet set up for attending #SCOPEsummit in February, please see below from the promo/registration details. It is going to…
For those of you who are not yet set up for attending #SCOPEsummit in February, please see below from the promo/registration details. It is going to…
Beliebt bei Artem Andrianov, PhD
-
Looking to make 2025 your strongest year yet? At MyRBQM Academy, we help you sharpen your #RBQM skills with practical, no-nonsense training. Explore…
Looking to make 2025 your strongest year yet? At MyRBQM Academy, we help you sharpen your #RBQM skills with practical, no-nonsense training. Explore…
Beliebt bei Artem Andrianov, PhD
Berufserfahrung
Ausbildung
-
Bayes Business School
–
Activities and Societies: M&A, New venture creation, London Squash club, ERT MBA group
Graduated with Honors in Finance, Quantitative Methods, Mergers and Acquisitions, etc. Focused on Finance, Corporate Strategy and New Product Development. During the study successfully fulfilled research projects for GlaxoSmithKline (GSK), Johnson & Johnson, ERT.
-
–
-
–
-
–
-
–
Bescheinigungen und Zertifikate
Veröffentlichungen
-
Adoption of RBQM in Academic Settings: Lessons Learned
Applied Clinical Trials
-
The PUEKS Project: Process Innovation in Clinical Trial Monitoring
Applied Clinical Trials Journal
The PUEKS Project (Process Innovation in Clinical Trial Monitoring) complements other cross-stakeholder collaborations such as the Clinical Trial Transformation Initiative (CTTI), TransCelerate Biopharma Inc., and the Metrics Champions Consortium (MCC) to innovate and improve clinical trial quality management.
Andere Autor:innenVeröffentlichung anzeigen -
ICH GCP Goes Risk Based
Applied Clinical Trials
The new upcoming GCP E6 (R2) addendum has the potential to reform clinical monitoring and clinical trial management. What changes does it bring to all of us? What does this mean for a pharmaceutical company, for a Contract Research Organization (CRO) and for an investigator in terms of changes to the processes of trial oversight, data collection and reporting and trial design and planning? In this article, you will find a structured summary and critical review of the new addendum, and as well…
The new upcoming GCP E6 (R2) addendum has the potential to reform clinical monitoring and clinical trial management. What changes does it bring to all of us? What does this mean for a pharmaceutical company, for a Contract Research Organization (CRO) and for an investigator in terms of changes to the processes of trial oversight, data collection and reporting and trial design and planning? In this article, you will find a structured summary and critical review of the new addendum, and as well as ideas on how to prepare for these regulatory changes.
Andere Autor:innenVeröffentlichung anzeigen -
GCP Change – New Risks for Biotech?
Going Public Biotechnology
The new upcoming GCP E6(R2) addendum reforms clinical monitoring and clinical trial management. Risk factors are an important component. What this means for a biotech company: clinical trial risks are easy to foresee, site level risks and operational risks are hard to detect; in this article, you will find a step by step approach to how to turn the new regulation to your best advantage.
-
Quality Risk Management as a Survival Kit: From Idea to Implementation
DIA Global Forum
Efficient risk management becomes a survival kit for a modern pharmaceutical company. How should one select from the available Risk-based Monitoring (RBM) solutions? This article explains the main principles of Risk-based Monitoring, refers to the changing regulatory environment (GCP addendum E6-R2) and categorizes available RBM technologies by IT infrastructure, data sourcing, assessment frequency, risk areas and feature-sets. Moreover, it provides a simple to follow framework for RBM…
Efficient risk management becomes a survival kit for a modern pharmaceutical company. How should one select from the available Risk-based Monitoring (RBM) solutions? This article explains the main principles of Risk-based Monitoring, refers to the changing regulatory environment (GCP addendum E6-R2) and categorizes available RBM technologies by IT infrastructure, data sourcing, assessment frequency, risk areas and feature-sets. Moreover, it provides a simple to follow framework for RBM technology selection and a systematic five-step RBM rollout consisting of: proof concept, pilot project, lessons learned, adjustment of RBM and final rollout.
Andere Autor:innenVeröffentlichung anzeigen -
How Do We Define Clinical Trial Data Quality if No Guidelines Exist?
Applied Clinical Trials
Many of us speak about the importance of clinical trial data quality and integrity, yet the lack of data quality standards and definitions introduces subjectivity risk in clinical trials.
Andere Autor:innenVeröffentlichung anzeigen -
Avoide Potential Pitfalls around RBM
Applied Clinical Trials, Risk-Based Monitoring E-Book
When implementing RBM, make sure patient safety and data quality are still at the forefront.
-
Can RBM Influence the Data Quality and Patient Safety Inversely?
Applied Clinicaltrials Online
“Never assume that something obvious is true,” a good friend of mine told me—a researcher with 20 years of experience, and one of the wisest men I have met in my life. Many years later, this advice would guide me to critically consider and analyze Risk-based Monitoring (RbM).
-
RbM Guidance Document: Ten Burning Questions about Risk-Based Study Management
Applied Clinical Trials Online
The RbM Consortium is a transnational alliance of quality risk management industry experts, risk-based technology firms, data analysts, and biopharmaceutical business strategists. Members of this group include WSQMS, PPH plus, Cyntegrity, and Annex Clinical. The objective of this collaboration is to improve awareness of Risk-based Monitoring (RbM) in clinical trials, to advise biopharmaceutical enterprises, medical device companies, CROs, study sponsors, and study sites on best practices, and…
The RbM Consortium is a transnational alliance of quality risk management industry experts, risk-based technology firms, data analysts, and biopharmaceutical business strategists. Members of this group include WSQMS, PPH plus, Cyntegrity, and Annex Clinical. The objective of this collaboration is to improve awareness of Risk-based Monitoring (RbM) in clinical trials, to advise biopharmaceutical enterprises, medical device companies, CROs, study sponsors, and study sites on best practices, and communicating the best implementation strategies on sound quality risk management systems, technologies, and business methodologies in RbM. This guidance document offers information about RbM strategies.
Andere Autor:innenVeröffentlichung anzeigen -
RbM Guidance Document: Ten Burning Questions about Risk-Based Study Management
Applied Clinical Trials Online
The RbM Consortium is a transnational alliance of quality risk management industry experts, risk-based technology firms, data analysts, and biopharmaceutical business strategists. Members of this group include WSQMS, PPH plus, Cyntegrity, and Annex Clinical. The objective of this collaboration is to improve awareness of Risk-based Monitoring (RbM) in clinical trials, to advise biopharmaceutical enterprises, medical device companies, CROs, study sponsors, and study sites on best practices, and…
The RbM Consortium is a transnational alliance of quality risk management industry experts, risk-based technology firms, data analysts, and biopharmaceutical business strategists. Members of this group include WSQMS, PPH plus, Cyntegrity, and Annex Clinical. The objective of this collaboration is to improve awareness of Risk-based Monitoring (RbM) in clinical trials, to advise biopharmaceutical enterprises, medical device companies, CROs, study sponsors, and study sites on best practices, and communicating the best implementation strategies on sound quality risk management systems, technologies, and business methodologies in RbM. This guidance document offers information about RbM strategies.
Andere Autor:innenVeröffentlichung anzeigen -
Case Study: Using RBM to Evaluate and Predict Site Engagement
Applied Clinical Trials
Clinical trial site engagement has been advocated as a critical component relating to a study’s performance and success, however, a minimum amount of data supports this connection. Researchers have acknowledged that medical engagement correlates with performance and innovation, nonetheless, direct causality is unclear...
Andere Autor:innenVeröffentlichung anzeigen
Auszeichnungen/Preise
-
MCC Champion
Metric Champion Consortium
"I am pleased to share the exciting news that you have been selected as a member of this year's group of MCC Champions - a special honor bestowed upon individuals who made significant contributions in 2016 to advancing the MCC mission to improve the efficiency, quality and effectiveness of clinical trials. Congratulations!"
Linda B. Sullivan
Co-Founder & President -
German Leadership Program
Cognos; InWEnt Capacity Building International
International internship in Germany, the initiative for educating prospective industry leaders
Sprachen
-
German
Verhandlungssicher
-
English
Verhandlungssicher
-
Latin
Grundkenntnisse
Organisationen
-
DGGF
member
–Heute -
DGPharMed
-
–Heute -
RBM Consortium
Member
–Heute -
DIA
-
–Heute
Erhaltene Empfehlungen
3 Personen haben Artem Andrianov, PhD empfohlen
Jetzt anmelden und ansehenWeitere Aktivitäten von Artem Andrianov, PhD
-
🚨Our December issue is LIVE🚨 A Look Ahead in eCOA for 2025🔺Accelerating Breakthroughs with Synthetic Clinical Trial Data🔺Why Mindset Matters in…
🚨Our December issue is LIVE🚨 A Look Ahead in eCOA for 2025🔺Accelerating Breakthroughs with Synthetic Clinical Trial Data🔺Why Mindset Matters in…
Beliebt bei Artem Andrianov, PhD
-
Great partnerships always begin with trust and belief!
Great partnerships always begin with trust and belief!
Geteilt von Artem Andrianov, PhD
-
🎉 We’re celebrating 6,000 LinkedIn followers! 🎉 What an incredible milestone! Thank you for being part of our journey! This achievement reflects…
🎉 We’re celebrating 6,000 LinkedIn followers! 🎉 What an incredible milestone! Thank you for being part of our journey! This achievement reflects…
Beliebt bei Artem Andrianov, PhD
-
How will AI transform the life sciences industry? 🤔 In an exclusive webcast, our VP and Practice Lead for Digital Strategy Greg Sterndale is joined…
How will AI transform the life sciences industry? 🤔 In an exclusive webcast, our VP and Practice Lead for Digital Strategy Greg Sterndale is joined…
Beliebt bei Artem Andrianov, PhD
-
ICH E6 R3 I am pleased to be presenting on this important topic with two of the Worhking Group members. Our round table approach will give a broad…
ICH E6 R3 I am pleased to be presenting on this important topic with two of the Worhking Group members. Our round table approach will give a broad…
Beliebt bei Artem Andrianov, PhD
-
"𝗦𝘁𝗮𝘁𝗶𝘀𝘁𝗶𝗰𝗮𝗹𝗹𝘆 𝘀𝗶𝗴𝗻𝗶𝗳𝗶𝗰𝗮𝗻𝘁" adds 𝘇𝗲𝗿𝗼 𝘃𝗮𝗹𝘂𝗲 to business decisions. The concept of statistical significance is…
"𝗦𝘁𝗮𝘁𝗶𝘀𝘁𝗶𝗰𝗮𝗹𝗹𝘆 𝘀𝗶𝗴𝗻𝗶𝗳𝗶𝗰𝗮𝗻𝘁" adds 𝘇𝗲𝗿𝗼 𝘃𝗮𝗹𝘂𝗲 to business decisions. The concept of statistical significance is…
Beliebt bei Artem Andrianov, PhD